secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0001558370-24-013318
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte appoints Cynthia Collins to Board; board expands to 10 members
----------------------------------------------------------------------

- Cynthia Collins appointed as Class II director effective Oct 14, 2024; board expands from 9 to 10.
- Collins to serve on Compensation Committee; receives 97,698 stock options (3-yr vest) and 51,679 RSUs (1-yr vest).
- Over 40 years biotech experience, including CEO of Editas Medicine; boards of Poseida (PSTX), Certara (CERT), and others.
- Disclosure notes past directorship at DermTech (OTC:DMTKQ) which filed Chapter 11 in June 2024; no other regulatory issues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837024013318/0001558370-24-013318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837024013318/mxct-20241014x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-013318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer